Figure 1

Plasma levels of lncRNAs in patients with CAD and controls. Plasma levels of H19 (A) and LIPCAR (B) are increased in patients with CAD compared with controls. No significant difference was observed in the plasma levels of THRIL (C), LincRNA-Cox2 (D), LincRNA-p21 (E), SLC26A4-AS1 (F), HULC (G), and APOA1-AS (H) between patients with CAD and controls. CAD, coronary artery disease; *P < 0.05.